Amendment to the Exclusive License AgreementExclusive License Agreement • August 5th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment to the Exclusive License Agreement (this “Amendment”) is effective as of May 16, 2016 (the “Amendment Effective Date”) by and between Five Prime Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at Two Corporate Drive, South San Francisco, CA 94080, USA (“FivePrime”) and Galaxy Biotech, LLC, a limited liability company organized and existing under the laws of the State of Delaware, having a place of business at 22830 San Juan Rd, Cupertino, CA 95014 (“Galaxy”). Galaxy and FivePrime are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
